# Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

> **NCT02176135** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Vaccine and Gene Therapy Institute, Florida**

## Conditions studied

- HIV

## Interventions

- **DRUG:** Auranofin

## Key facts

- **NCT ID:** NCT02176135
- **Lead sponsor:** Vaccine and Gene Therapy Institute, Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2016-01
- **Final completion:** 2017-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176135, "Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02176135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*